Alpine Woods Capital Investors LLC Has $1.76 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alpine Woods Capital Investors LLC lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,470 shares of the biopharmaceutical company’s stock after selling 47 shares during the period. Alpine Woods Capital Investors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,759,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in REGN. Sigma Planning Corp grew its stake in Regeneron Pharmaceuticals by 4.1% during the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 16 shares during the period. Entropy Technologies LP acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $420,000. GSA Capital Partners LLP acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $665,000. First National Trust Co boosted its holdings in Regeneron Pharmaceuticals by 48.5% in the third quarter. First National Trust Co now owns 306 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 100 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 1.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 1,298 shares of the biopharmaceutical company’s stock worth $1,365,000 after acquiring an additional 19 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $680.61 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $695.93 and its 200 day simple moving average is $840.01. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $74.41 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on REGN shares. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Finally, Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.